SKLB610 is an inhibitor of VEGFR2 that also inhibits PDGFR and FGFR2. SKLB610 exhibits anticancer chemotherapeutic and anti-angiogenic activities. In animal models of colorectal cancer and non-small cell lung cancer (NSCLC), SKLB610 decreases capillary tube formation, microvessel density, and tumor proliferation.
| Cas No. | 1125780-41-7 |
|---|---|
| Purity | ≥98% |
| Formula | C21H16F3N3O3 |
| Formula Wt. | 415.37 |
| IUPAC Name | N-Methyl-4-(4-{[3-(trifluoromethyl)benzoyl]amino}phenoxy)-2-pyridinecarboxamide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | S4244 Info Sheet PDF |
|---|
Luo X, Li S, Xie Y, et al. Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV. J Chromatogr Sci. 2013 Jan;51(1):17-20. PMID: 22710664.
Cao ZX, Zheng RL, Lin HJ, et al. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol Biochem. 2011;27(5):565-74. PMID: 21691074.
